Drug Discovery & DDS– category –
-
FDA Greenlights 24 Drugs in May 2026, Featuring AbbVie’s Decnupaz ADC and Shionogi’s Xocova COVID-19 Oral
BioWorld USA Overview The U.S. FDA approved 24 drugs in May 2026, marking the highest number of approvals in a single month this year, with eight being novel molecular entities (NMEs). This surge includes AbbVie's CD123-targeting antibod... -
FDA Greenlights Breakthrough TNBC Therapies, First-in-Class Hypertriglyceridemia Drug, and New Breast Cancer Maintenance Regimen
FDA USA Overview On June 24, 2026, the U.S. FDA announced pivotal approvals across several cancer and metabolic disease indications, introducing significant new therapeutic options. These include a breakthrough for triple-negative breast... -
Oral GLP-1 Aleniglipron Achieves 12% Weight Loss in Phase II, Poised to Transform Obesity Treatment
Health and Me / Northwestern University USA Overview The novel oral GLP-1 receptor agonist, aleniglipron, demonstrated an impressive average 12% body weight reduction over 36 weeks in obese or overweight patients during a Phase II clinic... -
Drug Discovery & DDS Weekly Report May 20, 2026
▼ ▼ ▼ If you found the infographic compelling and want to read the full Weekly Report, click below to download the Strategy Report. ▼ ▼ ▼ 📄 Drug Discovery & DDS Weekly Report — June 20, 2026 DrugDiscovery_DDS_WeeklyReport_EN_20260620.pd... -
Novo Nordisk’s Zenagamutide: Dual GLP-1/Amylin Agonist Delivers Significant Metabolic Gains in Type 2 Diabetes
Healio デンマーク Overview Novo Nordisk's novel unimolecular GLP-1/amylin receptor agonist, zenagamutide, has demonstrated significant reductions in HbA1c and body weight in adults with type 2 diabetes during its Phase 2 clinical trial. ... -
Precision Science Fuels Biopharma M&A Surge: Q1 2026 Hits $65B+, Marking Industry’s ‘Full Recovery’
BioSpace / PwC, Pharmaceutical Technology / PwC USA Overview PwC's latest report declares the biopharma ecosystem 'fully recovered,' with Q1 2026 M&A deal values exceeding $65 billion, marking the largest quarter since 2020. This rob... -
FDA Grants Accelerated Approval to AVLAYAH, a BBB-Penetrating Biologic, Ushering in a New Era for Brain Drug Delivery
Drug Delivery Leader USA Overview On March 25, 2026, the FDA granted accelerated approval to AVLAYAH (tividenofusp alfa-eknm), the first biologic engineered to traverse the blood-brain barrier (BBB). This landmark decision, following dec... -
Recipharm Infuses Millions into US Sterile Fill-Finish, Bolstering Advanced Therapy Manufacturing
Recipharm (プレスリリース), Fierce Pharma スウェーデン Overview Global CDMO Recipharm is making a multi-million dollar strategic investment to significantly enhance its US sterile fill-finish capabilities, addressing the surging demand f... -
Closing the Innovation Gap: Early CMC Risk Management and Robust Conjugation Strategies for ADCs and AOCs
Industry Publication Unknown Overview As Antibody-Drug Conjugates (ADCs) and Oligonucleotide-Drug Conjugates (AOCs) rapidly expand beyond oncology, early identification of Chemistry, Manufacturing, and Controls (CMC) risks and establishi... -
Hongene Biotech Leverages Chemoenzymatic Ligation to Scale CRISPR sgRNA Manufacturing
Industry Publication / Hongene Biotech Unknown Overview Hongene Biotech is pioneering a chemoenzymatic ligation technology to address the critical scalability challenges in producing single-guide RNA (sgRNA) for CRISPR gene editing. This...
